Truist raises target for Zymeworks stock to USD 34.00
Published on 10/08/2026 at 11:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zymeworks (ISIN US98985Y1082) had its Truist price target raised from USD 32.00 to USD 34.00 on October 7, 2026. According to Markets Insider, Truist kept a Buy rating while lifting the target ahead of Zymeworks quarterly results.
Truist lifts the target
The USD 2.00 increase represents 6.25 percent from the previous USD 32.00 target, giving investors a clear measure of the latest analyst revision. Truist also pointed to the need for visible revenue delivery and differentiated products as the company moves toward 2027, according to Markets Insider.
Guidance points to revenue
Zymeworks expects total 2026 revenue of USD 278 million to USD 292 million and adjusted EBITDA of USD 114 million to USD 128 million. The guidance followed the completion of the Theravance Biopharma acquisition on September 28, 2026, according to Zymeworks.
The same release said first-half 2026 YUPELRI sales reached USD 133.1 million and generated USD 38.4 million in collaboration revenue for Theravance Biopharma. That mix gives the revenue range a commercial component beyond Zymeworks internal drug development pipeline.
Analyst spread stays wide
MarketBeat listed 11 Buy ratings, one Hold and one Sell on October 7, 2026, with an average price target of USD 40.64. The spread between Truist's USD 34.00 target and that average shows that analysts do not share one valuation path for the post-acquisition story.
The same MarketBeat report placed Zymeworks market capitalization at USD 1.90 billion and cited a next earnings date of November 10, 2026. The stock's 52-week range was USD 16.00 to USD 31.34 in the Wall Street Journal market data page.
Trading snapshot stays neutral
Zymeworks stock was trading at EUR 23.54 at Lang & Schwarz on October 8, 2026 at 11:35 a.m. CEST, minus 0.72 percent versus the prior close of EUR 23.71 on October 7, 2026. The latest euro quote leaves the daily move below the threshold for a directional headline while the company works through its expanded revenue base.
The further course of trading is shown by the continuously updated real-time quote of Zymeworks stock.
Zymeworks stock facts
- Company: Zymeworks Inc.
- ISIN: US98985Y1082
- Ticker: ZYME
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 8, 2026, 11:35 a.m. CEST): EUR 23.54
- Change versus prior close: minus 0.72 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 23.71
- Market capitalization: USD 2.0 billion (as of October 7, 2026)
- 52-week range: USD 16.00-31.34 (as of September 28, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 10, 2026
